Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Accumulated Expenses for 10 consecutive years, with $12.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 2.93% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, up 2.93% year-over-year, with the annual reading at $12.3 million for FY2025, 2.93% up from the prior year.
  • Accumulated Expenses hit $12.3 million in Q4 2025 for Rocket Pharmaceuticals, up from $11.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2025 to a low of $449000.0 in Q1 2021.
  • Historically, Accumulated Expenses has averaged $5.6 million across 5 years, with a median of $4.2 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: tumbled 85.13% in 2021 and later soared 1280.14% in 2022.
  • Year by year, Accumulated Expenses stood at $725000.0 in 2021, then skyrocketed by 1280.14% to $10.0 million in 2022, then dropped by 0.76% to $9.9 million in 2023, then increased by 20.28% to $11.9 million in 2024, then grew by 2.93% to $12.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for RCKT at $12.3 million in Q4 2025, $11.4 million in Q3 2025, and $8.0 million in Q2 2025.